Aspergillosis and Diet: coping with weight loss, poor appetite, food avoidance and stomach symptoms
For: patients, carers, general practitioners, specialist nurses and other non-specialists
Last reviewed: 8 April 2026
Important: This page is general information. It does not replace advice from your own clinical team.
Key points
- Eating difficulties are common in aspergillosis, especially in chronic pulmonary aspergillosis (CPA) and in people who also have other lung disease.
- The problem is often not simply “poor appetite”. Breathlessness, cough, fatigue, reflux, nausea, altered taste and medicine side effects can all make eating difficult.
- Some people gradually cut out more and more foods because eating feels uncomfortable or because they have been told certain foods are “bad” for lung symptoms.
- For many patients, the main nutritional goal is not a “perfect” diet. It is getting enough energy, protein and fluids in ways that feel manageable.
- “Little and often”, food fortification and nourishing drinks are often more realistic than trying to eat three large meals a day.
- Ongoing weight loss, a very restricted diet, persistent nausea, reflux or difficulty eating most days should be discussed with a doctor, specialist team or dietitian.
Why diet can become a major problem in aspergillosis
Many people living with aspergillosis find that eating becomes much harder than it used to be. This is particularly important in chronic pulmonary aspergillosis (CPA), where weight loss, fatigue and general ill health are common features of the illness. In practical terms, the body may need more energy while the person is less able to eat comfortably.
Several problems can overlap:
- Breathing takes more effort, which can increase energy needs.
- Coughing or breathlessness can interrupt meals.
- Tiredness can make shopping, cooking and eating feel like hard work.
- Inflammation and chronic illness can reduce appetite and contribute to muscle loss.
- Antifungal treatment and other medicines can cause nausea, altered taste, indigestion or poor appetite.
- Reflux, bloating or early fullness may mean that even small meals feel uncomfortable.
For some patients this creates a vicious circle: eating becomes unpleasant, intake falls, weight drops, strength falls, and eating may then feel even more difficult.
Who is most affected?
Not every patient with aspergillosis has major nutritional problems, but some groups are more likely to struggle. This includes people with:
- Chronic pulmonary aspergillosis (CPA)
- pre-existing lung disease such as chronic obstructive pulmonary disease (COPD), bronchiectasis or previous tuberculosis
- long-term fatigue, breathlessness or coughing
- persistent nausea or reflux symptoms
- a history of recent unplanned weight loss
- side effects from antifungal or other medicines
- anxiety around eating because meals repeatedly trigger symptoms
Some people with allergic bronchopulmonary aspergillosis (ABPA) also report poor intake or nutritional difficulties, although the pattern may differ from CPA. In ABPA, steroid treatment, asthma burden, medicine effects and general symptom load may all influence diet.
How eating can become difficult
People often describe eating problems in ways that do not sound like a classic “nutrition” issue. They may say things like:
- “I get full after a few mouthfuls.”
- “I cannot face a proper meal.”
- “Eating makes me cough.”
- “I feel uncomfortable after food.”
- “Some foods seem to sit badly.”
- “I only eat a few safe foods now.”
These experiences are important. They suggest that the real problem may be a mixture of breathlessness, upper gastrointestinal symptoms, medicine effects and learned food avoidance, not simply a lack of willpower or poor food choices.
When eating shrinks into a “minimal diet”
Some patients end up eating very little, often because that feels safer or more manageable than trying to eat normally. A “minimal diet” may look like:
- very small amounts of food only once or twice a day
- mostly soft or liquid foods
- reliance on tea, toast, soup or yoghurt
- long gaps without eating
- skipping meals because eating feels exhausting
This is understandable, but it can become a serious problem. Small intake over time may lead to:
- weight loss
- loss of muscle mass
- greater weakness and fatigue
- slower recovery from illness
- reduced ability to cope with infections or treatment
If a patient is managing only tiny amounts of food, the first goal is often not to rebuild a “normal” diet immediately. It is to make intake easier, more comfortable and more nourishing.
Avoiding many food types
Another common pattern is gradual food restriction. Patients may stop eating several food groups because they believe these foods worsen mucus, cough, reflux, nausea or fungal disease.
Examples include avoiding:
- dairy products
- sweet foods
- bread or dry foods
- meat
- acidic foods
- foods linked in the mind to a previous bad episode
Sometimes there is a genuine reason for avoiding a particular food. For example, reflux may make acidic or very fatty foods uncomfortable, and a dry crumbly food may clearly trigger coughing. The difficulty is that repeated bad experiences can also lead to over-restriction, where more and more foods are cut out than is really necessary.
That can leave the diet low in calories, low in protein and very repetitive. In practice, the aim is usually to adapt foods rather than cut out whole food groups unless there is a clear reason to avoid them.
Could the stomach or gut be part of the problem?
Yes. This is often overlooked.
Some patients with aspergillosis describe symptoms that sound mainly digestive rather than respiratory, for example:
- nausea
- heartburn or reflux
- bloating
- feeling full very quickly
- upper abdominal discomfort
- reduced appetite after starting or changing medication
- alternating diarrhoea and constipation
There are several possible reasons:
- Medicine side effects, including antifungals
- Gastro-oesophageal reflux disease (GORD), which can also worsen cough
- reduced activity levels and chronic illness
- constipation, especially when intake is poor or medicines contribute
- co-existing gastrointestinal disease that is separate from aspergillosis
If eating repeatedly causes upper abdominal or chest discomfort, or if reflux and nausea are prominent, it is reasonable to think of this as a symptom needing review rather than simply a “fussy eating” problem.
Practical ways to make eating easier
Different things help different people, but these approaches are often more realistic than trying to push through large meals.
1. Think “little and often”
Many people do better with five or six small eating opportunities through the day instead of three big meals. That may mean a small breakfast, a mid-morning snack, a light lunch, a nourishing drink, an evening meal and a supper snack.
2. Lower the effort of eating
Soft, moist foods are often easier than dry, chewy or crumbly foods. Examples include:
- porridge
- yoghurt
- custard or rice pudding
- mashed potato with added butter or cheese
- scrambled eggs
- soup with cream or grated cheese
- stews, casseroles or sauced dishes
3. Use drinks as nutrition
For some patients, drinks are easier to manage than food. Nourishing options can include:
- milky drinks
- smoothies
- milkshakes
- fortified hot drinks
- commercial oral nutritional supplements if prescribed or advised
4. Rest before eating
If fatigue or breathlessness are major barriers, it can help to eat after a rest rather than after exertion. Some people find breakfast or lunch easier than an evening meal.
5. Sit upright and stay upright afterwards
This can be especially helpful when reflux, coughing or chest discomfort are part of the picture.
6. Slow the pace
It is acceptable to eat slowly and pause often. Some patients benefit from smaller mouthfuls and short breathing pauses between them.
7. Look for manageable variety
If the diet has become very narrow, widening it gently may be more successful than trying to overhaul everything at once.
How to support weight maintenance
When keeping weight on is difficult, the most useful approach is often to increase the energy and protein content of what is already being tolerated.
Food-first ideas
- Add butter, cream, cheese, yoghurt, milk powder or olive oil to foods where suitable.
- Choose full-fat products rather than “diet” versions if weight loss is a concern.
- Add grated cheese to soup, mashed potato, scrambled eggs or vegetables.
- Make porridge with milk rather than water.
- Keep easy snacks available, such as yoghurts, cheese and crackers, peanut butter, hummus, custard, rice pudding or milky desserts.
Protein matters
Protein helps preserve muscle. Good sources include:
- milk, yoghurt and cheese
- eggs
- meat, fish and poultry if tolerated
- beans, lentils and other pulses
- nut butters where suitable
Oral nutritional supplements
When food alone is not enough, a doctor or dietitian may suggest oral nutritional supplements. These are often used between meals rather than instead of meals. They can be particularly helpful when appetite is low or meal size is very limited.
In general UK nutrition practice, a “food first” approach is usually tried first where appropriate, but oral nutritional supplements are commonly used when someone is at higher risk of malnutrition or is unable to meet needs from food alone.
Food and medicine issues to remember
Food and medicine can interact in two main ways.
1. Medicines can affect eating
Antifungal treatment and other medicines may contribute to:
- nausea
- indigestion
- altered taste
- poor appetite
- bowel upset
If these symptoms started after a medicine was introduced or changed, it is worth discussing that with the prescribing team.
2. Food can affect medicines
Some antifungal medicines have specific instructions about when to take them in relation to food. For example:
- Itraconazole capsules are generally taken with or just after food, while itraconazole liquid is generally taken on an empty stomach.
- Voriconazole is usually taken on an empty stomach.
- Some medicines also have important interactions with antacids or acid-suppressing medicines.
Because formulations differ, and because other medicines may also interact, patients should follow the instructions they have been given for their exact preparation and check with a pharmacist or clinical team if unsure.
Grapefruit and other food interactions: some medicines have clinically important food interactions. Patients should check current advice for each medicine rather than relying on memory or online generalisations.
Common diet myths
Dairy always makes mucus worse
This is a very common belief. Current evidence does not show that dairy routinely increases lung mucus production for most people. Some people do notice a thicker mouth or throat feeling after milk, which may relate to texture rather than extra mucus. If dairy is well tolerated, it can be a useful source of calories and protein.
Sugar “feeds” aspergillosis, so it should be cut out completely
Patients often hear this online, but strict self-imposed restriction can be more harmful than helpful when someone is already struggling to maintain intake. For many patients with weight loss, the immediate nutritional priority is adequate calories and protein, not aggressive dietary exclusion.
There is a special anti-aspergillosis diet
There is no widely accepted specialist diet that treats aspergillosis itself. In routine practice, nutrition advice usually focuses on preventing or treating malnutrition, easing symptoms and managing medicine-related issues.
If eating is difficult, I should just avoid more foods
Sometimes a food really is hard to tolerate, but repeated restriction can shrink the diet too far. Often it is more useful to ask, “Can this be made easier to eat?” rather than “Should I cut this out altogether?”
When to seek medical help
Patients should speak to their doctor, specialist team or another qualified healthcare professional if they have any of the following:
- ongoing unplanned weight loss
- clothes, rings or dentures becoming looser
- difficulty eating most days
- a very narrow diet with only a few “safe” foods
- persistent nausea, reflux, bloating or abdominal discomfort
- increasing weakness or fatigue
- concerns that medicines are worsening appetite or stomach symptoms
It may be appropriate to ask about a dietitian referral, especially if intake has been poor for some time or there are signs of malnutrition.
Seek urgent medical advice if:
- food or fluids are being kept down very poorly
- there are signs of dehydration
- weight loss is rapid or severe
- pain, vomiting, swallowing difficulty or other worrying symptoms are developing
Common questions
Should I force myself to eat full meals?
Usually not. If full meals are consistently overwhelming, smaller and more frequent intake is often more successful.
Are liquid calories “cheating”?
No. For some people, nourishing drinks are one of the most practical ways to protect weight and strength.
What if I only manage a few foods?
That is still worth discussing. A restricted diet may be understandable, but it can increase nutritional risk over time.
What if dairy feels unpleasant?
Individual experience matters. If a food clearly feels uncomfortable, it may help to try alternatives or use smaller amounts in different forms. But many people do not need to exclude dairy automatically.
Could reflux be making my cough worse?
Yes, it can in some people. Reflux can irritate the upper airway and may contribute to cough or discomfort around meals.
When to seek medical advice
Ask for medical advice if you are losing weight, struggling to eat most days, developing a very restricted diet, or think nausea, reflux or medication side effects are affecting your intake. Ask urgently if you are becoming dehydrated, vomiting repeatedly, or your intake has become extremely poor.
Author and review information
Prepared for: aspergillosis.org
Purpose: general educational information for patients and non-specialists
Review note: Because medicine instructions can change between formulations and brands, patients should always check the current advice supplied with their own prescription and confirm uncertainties with a pharmacist or clinical team.
References and further reading
- Carter C, Muldoon EG, Kosmidis C. Chronic pulmonary aspergillosis - a guide for the general physician. 2024.
PubMed - Tashiro M, Takazono T, Izumikawa K. Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, diagnosis, treatment, and unresolved challenges. 2024.
Free full text - Roboubi A, et al. Allergic bronchopulmonary aspergillosis. 2023.
PubMed - Sunman B, et al. Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. 2020.
Free full text - Madhavan V, et al. Malnutrition in allergic bronchopulmonary aspergillosis complicating asthma. 2023.
Free full text - British Dietetic Association. Spotting and treating malnutrition.
BDA resource - BAPEN. Food first / food enrichment.
BAPEN resource - BAPEN / Malnutrition Pathway. Managing malnutrition in COPD.
PDF - NICE. Managing malnutrition in COPD, The Malnutrition Pathway.
NICE shared learning resource - NHS. Heartburn and acid reflux.
NHS advice - Cambridge University Hospitals NHS Foundation Trust. Dietary and lifestyle advice for adults with gastro-oesophageal reflux disease (GORD).
CUH advice - NICE BNF. Itraconazole.
BNF drug monograph - Manchester University NHS Foundation Trust, National Aspergillosis Centre. Patient Information: Itraconazole.
PDF - Manchester University NHS Foundation Trust, National Aspergillosis Centre. Patient Information: Voriconazole.
PDF - Oxford University Hospitals NHS Foundation Trust. Advice about antifungals.
PDF - Balfour-Lynn IM. Milk, mucus and myths. Archives of Disease in Childhood. 2019.
Article - Pinnock CB, Graham NM, Mylvaganam A. Relationship between milk intake and mucus production in adult volunteers challenged with rhinovirus-2. 1990.
PubMed - ASCIA. Milk, mucus and cough.
Patient resource
Diet and Aspergillosis: What Helps, What Doesn’t, and What Matters Most
Last reviewed: 8 April 2026
Many people living with aspergillosis ask whether diet can help “fight” the fungus, reduce symptoms, or improve recovery. This is completely understandable, particularly given the large amount of advice online suggesting that certain foods, supplements, or diets can control fungal disease.
This article explains what current evidence shows, what diet can and cannot do, and where it genuinely matters for people living with aspergillosis.
Core principle: Aspergillus-related disease is driven by what we breathe in and how the body responds — not by what we eat.
Contents
- Key points
- What do we mean by “no evidence”?
- How Aspergillus disease develops
- The role of airways, mucus and lung structure
- Immune response and inflammation
- Can food treat Aspergillus?
- Diet and ABPA (allergic disease)
- Allergy vs infection: why diet is often misunderstood
- Diet and CPA (chronic infection)
- Why nutrition still matters
- Steroids and diet
- Diet and antifungal medication
- Checking food–drug interactions
- Common diet myths (and why they persist)
- A practical, evidence-based approach
- When to seek help
- References
Key points
- There is no diet that treats aspergillosis.
- Aspergillus-related disease develops through inhalation of spores, changes in the lungs, and immune responses.
- Diet does not control Aspergillus growth in the lungs.
- Diet still matters for strength, weight, recovery, and treatment safety.
- Food can affect how medicines are absorbed and metabolised.
- Many popular online diet claims are based on misunderstood science, oversimplification, or marketing.
What do we mean by “no evidence”?
When this article says there is “no evidence” or “no strong evidence”, this does not mean that we are simply waiting for proof to arrive.
In most cases, it means one of two things:
- the idea has been studied and has not been shown to help real patients, or
- there is only laboratory or theoretical evidence, which does not translate into benefit in real-world disease
For example, fungi can grow in sugar-rich laboratory conditions. That does not mean eating sugar feeds Aspergillus in the lungs. The body tightly regulates blood glucose, and lung disease is far more complex than a laboratory culture dish.
Key message: when clinicians say there is “no evidence”, they usually mean an approach is unlikely to work in practice, not that it is a promising treatment that just has not been tested yet.
How Aspergillus disease develops
Aspergillus is a common environmental mould. People are exposed by breathing in microscopic spores from the air. Most people clear these spores without any problem.
Whether disease develops depends on the interaction between:
- the condition of the lungs
- how well mucus is cleared
- the immune response
In healthy lungs, inhaled spores are trapped in mucus, moved out of the airways, and removed by immune cells. When this system is disrupted, Aspergillus may persist or trigger inflammation. This is described in clinical reviews of pulmonary aspergillosis such as Kosmidis & Denning, 2015.
This process takes place in the respiratory system and is driven by inhalation — not diet.
The role of airways, mucus and lung structure
The lungs have several important defence systems. These include mucus, cilia (tiny hair-like structures that move mucus), and immune cells. Together, they help remove inhaled particles and organisms.
In conditions such as asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), or other chronic lung diseases:
- mucus may become thicker or harder to clear
- airways may be damaged or widened
- normal clearance may be less effective
This can make it easier for Aspergillus to remain in the lungs. In some people this contributes to allergic disease. In others, especially where there is structural damage, it can contribute to chronic infection.
These airway and lung-structure problems are not altered by avoiding particular foods.
Immune response and inflammation
In many people, particularly those with allergic forms of Aspergillus disease, symptoms are driven more by the immune system than by direct tissue invasion from the fungus.
For example, in allergic bronchopulmonary aspergillosis (ABPA), the body mounts an exaggerated allergic response to Aspergillus. This typically involves:
- raised IgE antibodies
- eosinophilic inflammation
- airway swelling and mucus production
Reviews of ABPA describe these immune processes in more detail, including the overlap with asthma and cystic fibrosis-related airway disease, for example Knutsen & Slavin, ABPA review.
These immune pathways are complex and are not controlled by specific foods.
Can food treat Aspergillus?
No specific food has been shown to treat Aspergillus-related lung disease.
You may come across claims about garlic, turmeric, coconut oil, probiotics, herbs, or “anti-fungal” foods. Some of these have shown antifungal effects in laboratory settings, but there is no reliable clinical evidence that eating them improves aspergillosis outcomes.
This is because:
- food is processed in the digestive system, not the lungs
- active compounds may not reach the lungs in useful amounts
- the biology of lung disease is much more complex than simple fungal growth in a dish
Diet can support the body, but it is not a treatment for Aspergillus disease.
Diet and ABPA (allergic disease)
In ABPA, the main problem is an allergic or immune reaction to Aspergillus. Diet does not switch that reaction on or off.
That means:
- food does not “feed” ABPA
- there is no evidence that an “anti-fungal diet” controls ABPA
- restrictive diets do not treat the underlying immune process
However, diet can become more important because many patients with ABPA are treated with prednisolone or other corticosteroids. These medicines can affect appetite, weight, blood sugar, and bone health. NHS information on prednisolone describes common effects such as weight gain, increased appetite, and longer-term bone risks: NHS Prednisolone guidance.
So in ABPA, diet often matters more in relation to treatment effects than in relation to the fungal trigger itself.
Allergy vs infection: why diet is often misunderstood
Many patients understandably ask whether a certain food might be “triggering” symptoms. This can be confusing because aspergillosis includes both allergic and infectious forms.
What matters here is the route of exposure:
- Aspergillus-related lung disease is driven by inhaled spores
- food enters the body through the digestive tract
Symptoms that seem to occur after eating may actually relate to:
- acid reflux
- throat irritation
- airway sensitivity
- coincidental fluctuation in symptoms
These may be real and troublesome, but they are not the same thing as diet directly driving Aspergillus disease.
Key message: Aspergillus-related lung symptoms are driven by what you breathe in and how your immune system responds — not by what you eat.
Diet and CPA (chronic infection)
Chronic pulmonary aspergillosis (CPA) is different from ABPA. CPA tends to occur in lungs that are already damaged or structurally abnormal, for example after tuberculosis, with bronchiectasis, or with COPD.
In CPA, the key issue is not food intake but the presence of abnormal lung tissue where Aspergillus can persist. This broader clinical picture is outlined in reviews such as Kosmidis & Denning, 2015.
Diet does not alter fungal growth directly, but it can matter because some people with CPA experience:
- weight loss
- fatigue
- low appetite
- reduced physical strength
In CPA, diet is therefore mainly about maintaining strength, resilience, and recovery — not about “starving” the fungus.
Why nutrition still matters
Although diet does not treat Aspergillus directly, nutrition still matters a great deal. Good nutrition supports the whole body, including the respiratory system.
Good nutrition can help support:
- muscle strength, including the muscles used for breathing
- energy levels
- general immune function
- recovery from illness and treatment
Poor nutrition, by contrast, can contribute to:
- tiredness
- lower resilience
- reduced strength
- slower recovery
This is one reason why very restrictive diets can be unhelpful, especially for patients already coping with chronic disease, breathlessness, or weight loss.
Steroids and diet
For patients taking corticosteroids such as prednisolone, diet becomes particularly relevant.
Important issues can include:
- increased appetite
- weight gain
- raised blood sugar
- fluid retention
- longer-term bone health
From a practical point of view, this is one of the strongest reasons to think carefully about diet in aspergillosis care. Here, diet is not being used to treat the fungus; it is helping patients cope with the effects of treatment and maintain overall health.
For longer-term steroid use, adequate calcium intake and attention to bone health may also be important. This is particularly relevant for people already at risk of osteoporosis.
Diet and antifungal medication
The clearest and most important direct link between diet and aspergillosis care is through medication.
Food can affect how medicines are absorbed, broken down, or cleared from the body.
Food–drug interactions
Some foods and drinks affect enzymes in the liver that metabolise drugs. A well-known example is grapefruit, which can interfere with CYP3A4 and change drug levels in the body.
Taking antifungals correctly
Some antifungal medicines are affected by food. For example, voriconazole is usually taken on an empty stomach so that absorption is more reliable. This is described in professional guidance such as the British National Formulary (BNF).
Supplements and herbal products
Supplements are often marketed as “natural”, but they can still interact with prescription medicines. Some herbal products may alter drug metabolism and therefore affect antifungal treatment.
Key message: diet rarely affects Aspergillus directly, but it can be very important in how your medicines work.
Checking food–drug interactions
Reliable sources for checking medicine and food interactions include:
- British National Formulary (BNF)
- patient information leaflets supplied with medicines
- Patient.info interaction checker
It is also important to understand the limits of specialist tools. Drug-interaction tools designed specifically for antifungals are very useful for drug–drug interactions, but they do not usually include food interactions in a comprehensive way.
The safest source of advice remains your pharmacist or clinical team.
Common diet myths (and why they persist)
Many people with aspergillosis come across strong claims online about diet and fungal disease. These often sound convincing, especially when symptoms are difficult to control and people understandably want something practical they can do.
However, most of these claims are based on misunderstandings of biology, laboratory research taken out of context, or commercial promotion.
Below are some of the most common myths, along with what current evidence suggests.
“Sugar feeds fungus”
This is one of the most common claims.
It comes from the fact that fungi can grow in sugar-rich laboratory conditions. However, this does not reflect what happens in the human body.
- blood sugar is tightly regulated
- Aspergillus in the lungs is not directly exposed to dietary sugar in the way people often imagine
- there are no clinical studies showing that reducing dietary sugar improves aspergillosis outcomes
Why it persists: it sounds intuitive, it is easy to repeat, and it fits with heavily marketed “anti-fungal” diet programmes.
“Milk and dairy increase mucus”
This is a very common concern in respiratory disease generally.
Research does not show that dairy increases mucus production in the lungs. Some people notice a thicker or coated feeling in the mouth and throat after milk, but that is different from producing more mucus in the airways.
- no good evidence of increased lung mucus
- no evidence that dairy worsens Aspergillus disease itself
Why it persists: the mouth and throat sensation after dairy can easily be mistaken for a lung effect.
“Yeast in food causes fungal infection”
Foods such as bread or fermented products may contain yeast, but yeast used in food is not the same thing as Aspergillus.
- food yeast and Aspergillus are different organisms
- Aspergillus-related lung disease is linked to inhalation of environmental spores, not eating yeast-containing foods
Why it persists: the word “fungus” is used broadly, which can blur important differences between very different organisms.
“Avoid foods made with mould”
Some patients are advised online to avoid blue cheese, mushrooms, or other foods associated with moulds.
There is no good evidence that eating these foods changes Aspergillosis in the lungs.
- the digestive and respiratory systems are separate
- food moulds are not the same thing as inhaled environmental Aspergillus exposure
Why it persists: when a disease involves mould, it feels logical to avoid all mould-associated foods, even though the biology does not support that approach.
“Low-carb or ketogenic diets can starve the fungus”
This idea grows out of the “sugar feeds fungus” claim.
However:
- the body keeps glucose within a narrow range
- lung infections are not directly altered by short-term dietary carbohydrate restriction
- there is no clinical evidence that low-carb or ketogenic diets improve aspergillosis outcomes
Why it persists: it sounds more scientific than it is, and it is frequently promoted in wellness and biohacking communities.
“Anti-fungal foods such as garlic, turmeric or coconut oil can treat aspergillosis”
Some of these substances show antifungal activity in laboratory experiments.
That is not the same as treating disease in people. The concentrations used in experiments are often very different from what is achievable through normal eating, and human lung disease is far more complex than a petri dish.
Why it persists: laboratory findings are often presented online as though they were proven clinical treatments.
“Detox diets or cleanses remove fungal infection”
There is no biological mechanism by which detox diets or juice cleanses remove Aspergillus from the lungs.
- the lungs are not “cleansed” through the digestive tract
- there is no clinical evidence supporting detox approaches in aspergillosis
Why it persists: detox language is emotionally appealing, especially when people feel unwell and want a sense of control.
“Candida overgrowth” diets apply to aspergillosis
Many patients come across “anti-Candida” diets and wonder whether the same advice applies to Aspergillus.
These diets often recommend:
- cutting out sugar
- avoiding carbohydrates
- removing yeast-containing foods
- following restrictive “anti-fungal” eating plans
However, these ideas are based on a different organism and a different part of the body.
Candida vs Aspergillus: important differences
- Candida is a yeast commonly found on the skin and in the gut
- Aspergillus is a mould in the environment that is inhaled into the lungs
Aspergillus-related disease such as ABPA or CPA affects the lungs and is driven by inhaled spores, not by changes in the gut.
Do “anti-Candida diets” affect Aspergillus?
There is no clinical evidence that diets designed to reduce Candida:
- affect Aspergillus in the lungs
- reduce allergic responses to Aspergillus
- improve outcomes in aspergillosis
These diets often rely on the same assumptions as other myths, especially the idea that “sugar feeds fungus”. Those assumptions do not fit how Aspergillus lung disease works.
What about the gut microbiome?
There is real scientific interest in the gut microbiome and its role in health. However, there is currently no evidence that changing diet to target gut fungi alters aspergillosis outcomes.
This is an area of research interest, but it is not a basis for dietary treatment at present.
Why these diets can be unhelpful
Restrictive anti-Candida or “anti-fungal” diets can sometimes lead to:
- reduced calorie intake
- weight loss
- nutritional imbalance
- anxiety around food
This can be particularly unhelpful in people with chronic lung disease who need to maintain strength and energy.
Key message: diets designed for “Candida overgrowth” are not relevant to aspergillosis and are not supported by evidence in this context.
“If symptoms improve after changing diet, the diet must be working”
This is a very understandable conclusion, but it can be misleading.
Symptoms in aspergillosis often fluctuate because of:
- natural variation in disease activity
- environmental exposure
- allergy activity
- medication changes
An improvement may happen at the same time as a dietary change without being caused by that change.
Advice from non-mainstream or alternative sources
Many people with long-term or difficult-to-control conditions look beyond standard medical care for additional answers. This is entirely understandable, especially when symptoms are persistent or uncertain.
You may come across advice from practitioners or online sources who describe themselves as offering “functional”, “integrative”, or “alternative” approaches. These often include:
- strict or highly restrictive diets
- “anti-fungal” or “detox” protocols
- long lists of supplements
- tests or diagnoses that are not widely used in NHS practice
Some of this advice may sound detailed or scientific. However, it is important to understand that:
- many of these approaches are not supported by clinical evidence in aspergillosis
- they may be based on theories that do not reflect how lung disease develops
- they are often not part of standard respiratory or infectious disease care
In some cases, following this advice can lead to:
- unnecessary dietary restriction
- weight loss or nutritional problems
- delays in receiving appropriate medical treatment
- confusion about symptoms and diagnosis
This does not mean that all non-mainstream approaches are harmful, but it does mean they should be approached with care.
Key message: if you are considering advice outside standard medical guidance, it is usually helpful to discuss it with your clinical team or pharmacist so it can be considered safely alongside your current treatment.
Overall message: many diet claims are based on ideas that sound plausible but do not reflect how aspergillosis works in the body.
A practical, evidence-based approach
For most people with aspergillosis, the most sensible and evidence-based approach is:
- eat a balanced diet
- maintain weight and strength
- include regular sources of protein
- avoid unnecessarily restrictive diets
- follow medicine-specific instructions carefully
- check food–drug interactions rather than relying on social media advice
Focus on supporting your body and treatment — not trying to treat Aspergillus through diet.
When to seek help
It may be worth asking for extra support if you are experiencing:
- unintentional weight loss
- poor appetite
- difficulty managing steroid-related appetite or weight changes
- concerns about blood sugar or bone health
- questions about food–drug interactions
Pharmacists, GPs, specialist teams, and where appropriate dietitians can all help with these issues.
References
- Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015.
- Warris A, Bercusson A, Armstrong-James D. Aspergillus colonization and antifungal immunity in cystic fibrosis patients. Med Mycol. 2019.
- Knutsen AP, Slavin RG. Reviews on allergic bronchopulmonary aspergillosis.
- NHS. Prednisolone guidance.
- British National Formulary (BNF).
- Patient.info interaction checker.
This article is for general information and should not replace advice from your own clinical team.
Cystic Fibrosis, CFTR Gene Variants, and Aspergillosis
Last reviewed: 8 April 2026
Some people with aspergillosis are told they have cystic fibrosis (CF), or that they carry a CFTR gene variant. This can be unexpected and may raise concerns about whether this explains their symptoms or diagnosis.
This article explains how cystic fibrosis and CFTR gene variants relate to Aspergillus-related lung disease, what current research shows, and—importantly—what conclusions should not be drawn.
Contents
- Key points
- Important reassurance
- What is cystic fibrosis?
- What is a CFTR gene variant?
- How CFTR affects the lungs
- How Aspergillus behaves in the lungs
- ABPA and cystic fibrosis
- CPA and cystic fibrosis
- Modern CF treatments and Aspergillus
- Does a CFTR variant explain symptoms?
- What should patients take from this?
- When to seek medical advice
- Conclusion
- References
Key points
- Most people with aspergillosis do not have cystic fibrosis.
- Most people with cystic fibrosis do not develop ABPA or CPA.
- ABPA is linked to mucus and immune responses, not just infection.
- CFTR variants may contribute to risk in some people, but are usually only one factor.
- CPA is mainly driven by structural lung damage, not CFTR genetics.
Important reassurance
Most people with aspergillosis do not have cystic fibrosis, and most people with cystic fibrosis do not develop Aspergillus-related disease.
Although these conditions can overlap, they are usually separate. Genetic findings such as CFTR variants should be interpreted carefully and in context.
What is cystic fibrosis?
Cystic fibrosis is a genetic condition caused by changes in the CFTR gene. This gene regulates salt and water movement across cells.
When CFTR function is reduced:
- mucus becomes thick and sticky
- airways are harder to clear
- microorganisms persist more easily
This creates an environment where bacteria and fungi can accumulate over time.
What is a CFTR gene variant?
CFTR variants range from severe mutations (causing cystic fibrosis) to mild or uncertain variants.
Carriers (with one variant):
- are common in the general population
- usually have no symptoms
- may have subtle effects in some cases
These subtle effects may include reduced mucus clearance or increased susceptibility to airway inflammation.
How CFTR affects the lungs
CFTR dysfunction affects the lungs in several key ways:
- Mucus dehydration: mucus becomes thick and difficult to clear
- Impaired clearance: particles and microbes remain in the airways
- Chronic inflammation: immune responses become exaggerated
This combination creates a “retention environment” where inhaled organisms—including Aspergillus—may persist.
How Aspergillus behaves in the lungs
Aspergillus is inhaled by everyone, but its effects vary depending on the lung environment.
- Healthy lungs: spores are cleared
- Impaired clearance: spores may persist
- Sensitive immune system: allergic reactions may develop
- Damaged lungs: chronic infection may develop
This explains why Aspergillus-related disease is diverse and depends heavily on underlying lung conditions.
ABPA and cystic fibrosis
ABPA is an allergic immune reaction to Aspergillus.
It is recognised in cystic fibrosis because:
- mucus retention increases exposure to Aspergillus
- immune responses can be exaggerated
However:
- Many CF patients never develop ABPA
- Most ABPA patients do not have CF
Some studies suggest CFTR variants may increase susceptibility, but this is not consistent across all research.
Key message: ABPA and CF can overlap, but one does not imply the other.
CPA and cystic fibrosis
CPA is a chronic fungal infection that develops in structurally damaged lungs.
The most important risk factor is:
pre-existing lung damage
This includes:
- bronchiectasis
- previous tuberculosis
- COPD
Cystic fibrosis can lead to bronchiectasis, and therefore indirectly increase CPA risk.
However:
- CPA is rarely driven directly by CFTR genetics
- most CPA patients do not have CF
Key message: CPA is primarily a disease of lung structure, not genetics.
Modern CF treatments and Aspergillus
CFTR modulators (such as elexacaftor/tezacaftor/ivacaftor) have transformed CF care.
They:
- improve CFTR function
- thin mucus
- improve clearance
Studies suggest:
- reduced Aspergillus detection in some patients
- fewer ABPA exacerbations in some cases
However:
- ABPA still occurs
- existing lung damage remains
- immune responses are not fully corrected
Overall: these therapies improve risk but do not eliminate Aspergillus-related disease.
Does a CFTR variant explain symptoms?
No single factor explains complex lung disease.
Symptoms may result from:
- underlying lung disease
- infection
- inflammation
- environmental exposure
A CFTR variant may contribute, but is rarely the sole cause.
What should patients take from this?
- CF and CFTR variants can sometimes contribute
- ABPA has the strongest connection
- CPA is mainly driven by lung damage
- Most patients with aspergillosis do not have CF
When to seek medical advice
Seek advice if symptoms worsen, change, or include coughing up blood, fever, or chest pain.
Conclusion
Cystic fibrosis and CFTR gene variants can play a role in some patients with Aspergillus-related lung disease, particularly where mucus clearance is affected. However, they should not be overemphasised. In most cases, they are just one part of a broader clinical picture involving lung structure, immune response, and environmental exposure.
References
- Miller PW et al. (1996)
- Marchand E et al. (2001)
- Eaton TE et al. (2002)
- Agarwal R et al. (2012)
- Chaudhary N et al. (2012)
- Warris A et al. (2019)
- Gamaletsou MN et al. (2018)
- Kosmidis C & Denning DW (2015)
- Moldoveanu B et al. (2021)
- Malik HS et al. (2025)
- Zeng C et al. (2025)
- Bendixen MP et al. (2025)
This article is for general information and does not replace advice from your clinical team.
Real Questions. Clear Answers. Practical Support for People Living with Aspergillosis.
If you live with aspergillosis, or support someone who does, you will know how many questions can come up between appointments. Some are about symptoms. Some are about treatment. Some are about day-to-day life, side effects, monitoring, damp, mould, travel, fatigue, anxiety, or simply trying to understand what is happening.
That is why we have built and continue to expand our Patient Questions & Latest Articles section.
This part of our website brings together detailed answers to the kinds of questions patients and carers actually ask. Many of these articles began as real questions raised in our support meetings and online communities, then developed into fuller explanations so that others could benefit too.
Why this section is useful
Living with aspergillosis often means having to manage a lot of uncertainty. Information can be difficult to find, hard to interpret, or scattered across different places. We wanted to create a space that is easier to use: a place where people can browse practical topics, explore recent articles, and find trustworthy explanations written with patients and carers in mind.
Some people arrive with one urgent question. Others simply want to browse and see whether someone else has already asked the same thing. This section is designed to help with both.
What you will find there
- Answers to common patient and carer questions
- Detailed articles on symptoms, treatments, tests, monitoring, and side effects
- Practical explainers on issues such as damp, mould, air quality, medicines, and coping day to day
- Recent updates and newly published articles in one place
- Links into wider resources across our website
You do not need to read everything from start to finish. You can dip in when a particular question comes up, browse recent topics, or use the search function to look for something specific.
Built around real concerns
One of the strengths of this section is that it is grounded in real experience. The topics are not chosen at random. They reflect the concerns patients and carers bring to us repeatedly: the things people worry about, struggle to understand, or need explained more clearly.
That means the content is often practical, specific, and directly relevant to everyday life with aspergillosis.
Part of a wider knowledge base
If you want to browse recent questions and articles, this section is a very good place to start. If you are looking for more structured background information on aspergillosis, symptoms, tests, treatments, and monitoring, you can also move on from there to our wider Knowledge Hub.
Together, these resources are intended to make it easier for patients, families, and carers to find the information they need, when they need it.
Please use health information safely
As always, our website is here to support understanding, not replace medical advice from your own clinical team. We hope these articles help people feel better informed, better prepared, and better able to ask the right questions, but personal medical decisions should still be made with the professionals looking after your care.
Take a look
Explore the full section here:
Patient Questions & Latest Articles
If you think others may find it helpful, please feel free to share it.
Weekly Aspergillosis Research Update: 31 March – 7 April 2026
This week’s research reinforces several consistent themes in aspergillosis: ongoing diagnostic confusion (particularly with tuberculosis and cancer), increasing movement toward precision medicine, and continued development of both antifungal therapies and biomarkers. There is also a growing emphasis on host-pathogen interactions rather than fungal burden alone.
Key Highlights
- Isavuconazole levels can become unexpectedly high due to genetics and drug interactions.
- Chronic pulmonary aspergillosis (CPA) can mimic lung cancer, risking delayed diagnosis.
- New biomarker (EDN) for ABPA shows promise for diagnosis and monitoring.
- Azole resistance research highlights differences between Aspergillus species.
- New antifungal approaches emerging (olorofim, nitroxoline).
- Host response is central – fibroblasts and immune pathways actively influence disease.
- TB vs aspergillosis confusion persists in real-world settings.
Contents
- Clinical & Diagnostic Studies
- Treatment & Pharmacology
- Biology, Immunology & Resistance
- Biomarkers & Diagnostics
- Wider Context
Clinical & Diagnostic Studies
CPA mistaken for lung cancer
Paper: PubMed
A case report describes chronic pulmonary aspergillosis presenting as suspected lung malignancy in a patient with asthma and ABPA overlap.
Why this matters: CPA continues to be misdiagnosed due to tumour-like imaging appearances. This reinforces the need to consider fungal disease in patients with underlying lung conditions.
Invasive sinus aspergillosis causing bone destruction
Paper: Free full text
Granulomatous invasive aspergillosis led to facial bone destruction and neurological symptoms.
Why this matters: Delayed diagnosis of invasive disease can lead to severe structural damage. Early imaging and specialist input are critical.
Aspergillus infection in suspected TB patients
Paper: PubMed
Study shows overlap between tuberculosis and aspergillosis in symptomatic patients.
Why this matters: Persistent global issue—shared symptoms delay correct diagnosis and treatment, particularly relevant for CPA pathways.
Invasive aspergillosis in critical illness
Paper: PubMed
Case of invasive pulmonary aspergillosis in a patient with severe viral illness.
Why this matters: Reinforces that aspergillosis is not limited to traditional risk groups and can complicate severe systemic illness.
Treatment & Pharmacology
Isavuconazole toxicity linked to genetics
Paper: Free full text
Case report of supratherapeutic isavuconazole levels linked to CYP3A5 genotype and interacting medications.
Why this matters: Even “predictable” antifungals show variability. Supports therapeutic drug monitoring and future personalised dosing approaches.
Olorofim pharmacokinetics
Paper: PubMed
Study demonstrates tissue distribution of olorofim in preclinical models.
Why this matters: Supports ongoing development of a key next-generation antifungal, particularly for resistant disease.
Nitroxoline shows antifungal activity
Paper: PubMed
Repurposed drug demonstrates activity against Aspergillus via copper disruption and oxidative stress.
Why this matters: Highlights potential for non-azole antifungal strategies in future treatment.
Biology, Immunology & Resistance
Azole resistance and Aspergillus genomics
Paper: PubMed
Genomic study of Aspergillus section Fumigati explores resistance mechanisms and pathogenicity.
Why this matters: Different species may respond differently to antifungals—accurate identification is increasingly important.
Fibroblasts actively support lung defence
Paper: PubMed
Study shows fibroblasts contribute to immune defence and tissue repair during infection.
Why this matters: Disease outcomes depend on host response, not just fungal burden—important for future therapies.
Immune pathway targeting in fungal keratitis
Paper: PubMed
PIM1 inhibition reduces inflammation via STING pathway signalling.
Why this matters: Supports growing interest in targeting immune pathways alongside antifungal therapy.
Biomarkers & Diagnostics
Eosinophil-derived neurotoxin (EDN) in ABPA
Paper: PubMed
EDN proposed as a biomarker for allergic bronchopulmonary aspergillosis.
Why this matters: Could improve diagnosis and monitoring, helping distinguish ABPA from asthma or sensitisation alone.
Commentary on ISHAM ABPA guidelines
Paper: PubMed
Discussion of updated international guidance on ABPA diagnosis and management.
Why this matters: Highlights ongoing refinement of diagnostic criteria and classification systems.
Wider Context
Fungal extracellular vesicles
Paper: PubMed
Review of fungal vesicles in pathogenesis and host interaction.
Why this matters: Emerging area that may influence future diagnostics and therapies.
Aspergillosis in broader disease settings
Why this matters: Aspergillosis continues to appear across a wide range of conditions, particularly in critically ill or immunocompromised patients.
Overall Interpretation
This week’s literature reinforces several strategic priorities:
- Earlier and more accurate diagnosis remains essential, particularly in distinguishing CPA from TB and cancer.
- Precision medicine is advancing, with growing roles for pharmacogenomics, drug monitoring, and species-level identification.
- New antifungal options are progressing, but remain largely in development.
- Host response is increasingly recognised as central to disease progression and outcomes.
Overall, the field continues to move toward more personalised, biology-driven approaches to diagnosis and management.
Mould, “Toxins” and Aspergillus: Understanding What’s True and What Isn’t
Last reviewed: April 2026
Key points
- Exposure to mould is not the same as having aspergillosis.
- Aspergillus is a common environmental fungus that most people inhale daily.
- “Mycotoxin” and “detox” explanations are common online but are not part of standard diagnosis.
- Symptoms usually arise from a combination of lung disease, infection, inflammation, and environment.
- Diagnosis relies on clinical tests (scans, blood tests, microbiology), not environmental testing alone.
- Specialist home testing is sometimes used—but only in specific clinical situations.
A guide for patients and carers
Many people with lung conditions come across information linking mould exposure, toxins, and Aspergillus infections. Some of this information can be helpful—but much of it can also be confusing.
This article explains the most common misunderstandings and what current medical practice actually relies on.
Important: Some tests measure exposure—but medical diagnosis requires evidence of disease.
Contents
- Why this topic is confusing
- Mould exposure vs Aspergillus disease
- Mycotoxins and “detox” claims
- Why “mould toxin tests” are not used diagnostically
- Why symptoms don’t have one single cause
- How Aspergillus conditions are actually diagnosed
- When home testing may be used
- What matters most for patients
Why this topic is confusing
- Mould is visible and easy to focus on
- Symptoms (fatigue, cough, breathlessness) are non-specific
- Online information often mixes different conditions together
This can lead to the idea that one single cause—such as “mould toxicity”—explains everything. In practice, respiratory conditions are usually more complex.
Mould exposure vs Aspergillus disease
Mould exposure
- Common in homes and outdoor air
- Can irritate airways
- May worsen symptoms
Aspergillus disease
- Occurs in specific medical contexts
- Related to lung structure and immune response
- Requires clinical diagnosis
Important context: Aspergillus spores are present in the air we breathe every day. Most people inhale them without developing disease.
Mycotoxins and “detox” claims
You may see references to:
- “Mycotoxin illness”
- “Die-off reactions”
- “Binders” to remove toxins
These ideas are widely discussed online, but they are not part of standard medical diagnosis or treatment for Aspergillus lung conditions.
This does not mean symptoms are not real. It means they are usually explained through:
- Inflammation
- Infection
- Underlying lung disease
Why “mould toxin tests” are not used diagnostically
Exposure is common
Many people have detectable environmental exposure, so results are not specific.
Results do not match symptoms reliably
Levels do not consistently correlate with disease or severity.
Lack of standardisation
Different labs use different methods, making interpretation difficult.
Not part of clinical guidelines
Major respiratory guidelines do not include these tests in diagnosing Aspergillus conditions.
Risk of confusion
- May cause unnecessary concern
- May lead to unproven treatments
Why symptoms don’t have one single cause
Symptoms often arise from a combination of:
- Underlying lung disease
- Inflammation
- Infection (fungal or bacterial)
- Environmental triggers (pollution, damp)
This is why symptoms can fluctuate and may not respond to a single explanation or treatment.
How Aspergillus conditions are actually diagnosed
Diagnosis is based on a combination of:
- CT imaging
- Blood tests (e.g. IgE, IgG)
- Microbiology (sputum or bronchoscopy)
Environmental testing alone is not sufficient to diagnose disease.
When home testing may be used
In some cases, specialist teams (for example via the Mycology Reference Centre Manchester) may arrange targeted environmental sampling.
This is different from commercial testing and focuses on:
- Specific clinically relevant fungi (e.g. Aspergillus species)
- Known allergens or pathogens
Why it is done
- Established Aspergillus-related disease
- Unexplained or persistent symptoms
- Concern about ongoing exposure
This testing is used to answer specific clinical questions and is interpreted alongside medical findings.
What matters most for patients
- Work with your clinical team for diagnosis and treatment
- Address damp and mould in your home
- Focus on practical steps that improve symptoms
- Avoid relying on a single explanation for complex symptoms
Final takeaway
Mould, environment, and Aspergillus are connected—but not in a simple cause-and-effect way.
Understanding this helps you focus on what is most likely to improve your health: appropriate treatment, good living conditions, and ongoing monitoring.
Author: aspergillosis.org
Note: Educational content only – not medical advice.
Indoor Air Quality, Damp, Mould and Aspergillus
Last reviewed: April 2026
Key points
- Indoor air problems usually relate to pollution, damp, or mould—these are different but can overlap.
- Aspergillus is a normal part of the environment and not automatically a sign of a problem indoors.
- Damp and mould can worsen breathing symptoms and should be taken seriously.
- Fixing the underlying moisture problem is more important than cleaning visible mould.
- Knowing who to contact (GP, landlord, council) is key to resolving problems.
Looking for broader information about the air you breathe? See our Clean Air and Lung Health guide for information about indoor and outdoor air pollution, ventilation, fungal spores and air filtration.
Indoor Air Quality, Damp, Mould and Aspergillus
A practical guide for patients
Many people with aspergillosis or other lung conditions are concerned about the air inside their home. This article explains how indoor air quality works, how to recognise problems, and what steps you can take to improve your environment.
Contents
- What affects indoor air?
- Three common problems
- Aspergillus in the home
- Damp and mould
- Symptoms and health effects
- Identifying problems
- Getting the right help
- Practical steps
- Air purifiers
What affects indoor air?
Indoor air quality is influenced by both indoor and outdoor factors. People spend most of their time indoors, so even small issues can have a noticeable effect on health.
Indoor air can be affected by:
- Outdoor pollution entering the building
- Damp and moisture
- Mould growth
- Cooking, heating, and cleaning products
- Dust and particles
Three common indoor air problems
1. Indoor air pollution
- Particles from cooking, heating, and candles
- Outdoor pollution enters indoors
2. Damp (moisture)
- Condensation, leaks, poor ventilation
- Creates conditions for mould growth
3. Mould
- Visible fungal growth on surfaces
- Releases spores into the air
Aspergillus in the home
Aspergillus is a common environmental fungus found in air, dust, and soil.
This means:
- Everyone breathes in Aspergillus spores regularly
- Indoor exposure is not unusual
Important: Exposure does not equal disease. Aspergillosis depends on lung health and immune response—not just environment.
Damp and mould
Damp and mould are important because they can affect respiratory health. Damp homes are linked with increased respiratory symptoms and illness.
UK guidance highlights that damp and mould can produce irritants and spores that affect the lungs and should be addressed promptly.
Symptoms and health effects
Indoor air problems may contribute to:
- Cough
- Breathlessness
- Wheeze
- Chest tightness
- Fatigue
These symptoms often overlap with infection or underlying disease, making them difficult to interpret.
Identifying problems
Signs of damp
- Condensation on windows
- Cold or damp walls
- Peeling paint or wallpaper
- Musty smell
Signs of mould
- Black or green patches
- Mould returning after cleaning
- Growth behind furniture or in corners
Hidden issues
- Persistent damp smell
- Symptoms are worse in certain rooms
Getting the right help
1. Your healthcare team
- If symptoms worsen
- If you suspect your environment is affecting your health
2. Landlord or housing provider
- Report problems early
- Keep records (photos, dates)
UK guidance makes clear that damp and mould should be addressed promptly and not ignored.
3. Local council
- If landlord does not act
- If health is affected
Further reading
See more detailed guidance and support resources here:
Housing, damp and mould articles (aspergillosis.org)
Practical steps
- Improve ventilation (especially kitchens and bathrooms)
- Reduce moisture
- Address leaks quickly
- Clean small mould areas safely
Air purifiers
Air purifiers can reduce airborne particles, but:
- They do not fix damp
- They do not remove mould from surfaces
- They do not treat aspergillosis
Final takeaway
Indoor air problems are common and often manageable. The key is to:
- Recognise the signs early
- Address moisture and mould properly
- Seek help when needed
Author: aspergillosis.org
Note: This article is for general education and does not replace medical advice.
Outdoor Air Pollution and Aspergillosis
Last reviewed: April 2026
Key points
- Harmful air pollution can be visible or invisible.
- The Air Quality Index (AQI) is more reliable than how the air looks.
- Air pollution comes from natural, industrial, and everyday urban sources.
- Staying indoors can reduce exposure, but it does not remove it completely.
- People with aspergillosis, asthma, or bronchiectasis may be more sensitive to polluted air.
- Simple steps such as checking AQI, closing windows, and using filtration can help reduce exposure.
A practical guide for patients with lung conditions
Air pollution can make breathing symptoms worse for many people, especially those with existing lung disease. If you live with aspergillosis, asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), or other long-term lung problems, outdoor air quality can make a noticeable difference to how you feel day to day.
This guide explains what outdoor air pollution is, where it comes from, how to judge risk, what practical steps may help reduce exposure, and how to think sensibly about buying an air purifier.
Contents
- What is outdoor air pollution?
- Where does it come from?
- Visible or invisible pollution
- Understanding AQI (Air Quality Index)
- Where to check AQI
- Why air pollution matters in aspergillosis
- Dust storms, haze and extreme events
- How much protection does staying indoors give?
- Practical ways to reduce exposure
- Masks and air filtration
- Buying an air purifier: what matters and what does not
- Travel and changing environments
- Common misconceptions
- Managing your condition during high air pollution
- When to seek medical help
- References
What is outdoor air pollution?
Outdoor air pollution is a mixture of particles and gases in the air that can irritate the lungs and worsen breathing symptoms.
The main pollutants discussed in health guidance include:
- PM2.5 – very fine particles small enough to travel deep into the lungs
- PM10 – slightly larger particles that can still irritate the airways
- Nitrogen dioxide (NO2) – often linked to traffic and combustion
- Ozone (O3) – a gas that can irritate the lungs, especially in hot weather
- Smoke, dust and soot – depending on local conditions
Some of these pollutants are easy to see, but some are not. This is one reason why it is important not to rely only on appearance when judging air quality.
Where does it come from?
Outdoor air pollution usually comes from a combination of sources, not just one.
Natural sources
- Desert dust or sandstorms
- Wildfire smoke
- Wind-blown soil and dust
- Pollen (not usually included in AQI in the same way, but still relevant for symptoms)
Commercial and industrial sources
- Factories
- Power stations
- Shipping emissions
- Aviation emissions
- Construction and demolition dust
Domestic and urban sources
- Road traffic
- Heating systems
- Wood burners and solid fuel burning
- Cooking emissions in densely populated areas
In some situations, one source clearly dominates. For example, a severe dust event in North Africa or the Middle East may be mainly caused by natural desert dust. In a busy city, day-to-day pollution may be more strongly linked to traffic, heating, and industry. In many real-life situations, however, several sources are contributing at the same time.
Visible or invisible pollution
One of the most important things for patients to know is that harmful air pollution can be visible or invisible.
Visible pollution
- Dust or sand in the air
- Smoke
- Grey or brown smog
- Heavy haze
Invisible pollution
- Fine particles such as PM2.5
- Gases such as ozone or nitrogen dioxide
Clear sky does not always mean clean air. Equally, hazy air is not always the only dangerous situation. Some invisible pollutants can be especially harmful because they are easy to miss and can still reach deep into the lungs.
Key message: If you can see it, it may be harmful. If you cannot see it, it still may be harmful.
Understanding AQI (Air Quality Index)
The Air Quality Index (AQI) is often the most useful practical tool for patients. It gives a simple way of describing how healthy or unhealthy the air is likely to be.
| AQI | Meaning |
|---|---|
| 0–50 | Good |
| 51–100 | Moderate |
| 101–150 | Unhealthy for sensitive groups |
| 151–200 | Unhealthy |
| 201–300 | Very unhealthy |
| 300+ | Hazardous |
Very high readings can occur in severe dust events, smoke events, or heavily polluted urban conditions. For patients with lung disease, even levels well below the highest categories may still trigger symptoms.
Why AQI matters more than appearance
AQI can help you judge risk more reliably than what you can see or smell. Dust may have no obvious smell. Fine particles may be invisible. Air that looks like fog may actually be carrying a heavy particle load. Because of this, it is usually safer to trust the AQI reading rather than appearance alone.
Where to check AQI
Reliable sources for checking air quality include:
- QAir AirVisual
– widely used internationally, with real-time air quality data, forecasts, and health guidance - UK Department for Environment, Food & Rural Affairs (DEFRA) – UK-AIR
– official UK air quality data and health advice - Plume Labs
– useful for air-quality maps and forecasts - Windy
– helpful for visualising dust, smoke and weather patterns
For most people, it is best to use one app consistently, and occasionally cross-check with a second source if readings seem unusual.
Why air pollution matters in aspergillosis
People living with aspergillosis may already have lungs that are inflamed, structurally damaged, or more easily irritated. This may include people with:
- Allergic bronchopulmonary aspergillosis (ABPA)
- Chronic pulmonary aspergillosis (CPA)
- Bronchiectasis
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Air pollution can potentially worsen:
- Cough
- Breathlessness
- Chest tightness
- Wheeze
- Mucus production
- General irritation of the airways
It can also make it harder to work out what is causing symptoms. A flare in symptoms is not always due to infection. Sometimes symptoms may be made worse by air pollution, airway irritation, or inflammation, even when there is no new infection.
Dust storms, haze and extreme events
In some parts of the world, especially in North Africa and the Middle East, very high AQI readings are often caused by dust and sand in the air. This can sometimes be mistaken for fog.
Clues that this may be dust rather than fog include:
- Very high AQI readings
- Dry-looking haze rather than damp mist
- Dust collecting on surfaces
- Weather reports mentioning dust, sand, or reduced visibility
Dust does not always have a noticeable smell, so the absence of smell does not mean the air is safe.
How much protection does staying indoors give?

Staying indoors usually does help, but the amount of protection varies.
Typical home with windows closed
In general terms, staying indoors with windows closed may reduce exposure by around 30% to 70%, depending on:
- How well sealed the building is
- Whether windows or doors are being opened
- The age and condition of the property
- How long the pollution event lasts
Indoors with HEPA filtration
Using a correctly sized High Efficiency Particulate Air (HEPA) purifier can improve indoor air further. In some situations, this may reduce indoor particle exposure by around 50% to 90% or more.
Important limits
- Fine particles can still get indoors
- Older or drafty buildings may offer less protection
- Opening windows can quickly increase indoor particle levels again
The realistic goal is usually to reduce exposure as much as possible, not to expect complete protection.
Practical ways to reduce exposure
When outdoor AQI is high, the following steps may help:
- Stay indoors as much as possible
- Keep windows and doors closed
- Avoid strenuous outdoor activity
- Use air filtration if you have it
- Delay non-essential trips outdoors if practical
- Check AQI more than once per day during unstable conditions
For some people, symptoms may still occur even indoors. If so, it may help to reduce physical activity, keep rescue medication available if prescribed, and monitor symptoms closely.
Masks and air filtration
Masks
Well-fitted particle-filtering masks such as FFP2 or FFP3 may reduce exposure to fine particles when you need to go outdoors. Their usefulness depends heavily on fit, comfort, and wearing them correctly.
Not everyone can tolerate masks easily, especially if they are already short of breath, so they are not always a complete solution.
Air purifiers
A HEPA purifier may be especially useful in the room where you spend the most time, such as a bedroom or living room. Performance depends on:
- Correct room size
- Good maintenance of filters
- Keeping windows closed during high pollution periods
Buying an air purifier: what matters and what does not
Air purifiers can help reduce indoor particle levels, but it is important to be realistic about what they can and cannot do.
Important: An air purifier does not treat aspergillosis, does not cure asthma or bronchiectasis, and does not remove all particles. It is best thought of as one way to reduce exposure.
What matters most
- True HEPA filtration (or a clearly specified high-efficiency particle filter)
- Room-size coverage that matches the room where it will be used
- Clean Air Delivery Rate (CADR), where provided
- Noise level, especially if used in a bedroom
- Replacement filter cost and availability
What these terms mean
True HEPA: This usually means the purifier is designed to remove very small airborne particles efficiently. For patients concerned about dust and polluted air, this is generally more important than extra “smart” features.
Room size: A purifier that is too small for the room may not make much difference. It is usually better to buy the correct size for the room where you spend the most time than to buy a very cheap device that cannot handle the space.
CADR: This is a measure of how quickly a purifier can clean the air. Higher CADR usually means faster particle removal, though room size and real-life use still matter.
What to be cautious about
- Very cheap devices with vague claims but no clear filter specification
- Small USB-powered “desk purifiers” claiming to clean large rooms
- Ioniser-only devices with no proper particulate filter
- Products that make sweeping medical claims
Practical buying advice
- Start with the room you use most, often the bedroom or living room
- Choose a purifier that is rated for that room size
- Check how often filters need replacing and how much replacements cost
- Read the real specifications, not just the marketing headline
- If you are noise-sensitive, look at the sleep-mode or low-speed sound level
Reasonable expectations
Used properly, a good air purifier may make a meaningful difference during high pollution periods, especially when combined with keeping windows closed. However, it is only one part of managing exposure.
Travel and changing environments
Air quality can change dramatically between regions and countries. Some places have persistent urban pollution, while others may experience sudden dust events, wildfire smoke, or seasonal changes.
If you are travelling, it may help to:
- Check local AQI before travel and during your stay
- Be aware of seasonal dust or wildfire risks
- Know where you can spend time indoors if air quality worsens
- Keep regular medications with you
This can be particularly important if you already know that poor air quality tends to worsen your symptoms.
Common misconceptions
Myth: “If I cannot see pollution, it is safe.”
Fact: Invisible pollution such as PM2.5 and gases can still be harmful.
Myth: “If the air looks foggy, it must just be water vapour.”
Fact: Hazy air can sometimes be caused by dust or pollution rather than fog.
Myth: “Staying indoors completely solves the problem.”
Fact: Staying indoors usually reduces exposure, but does not remove it completely.
Myth: “If my symptoms worsen, it must be an infection.”
Fact: Pollution and airway irritation can also worsen symptoms.
Myth: “Air pollution is always caused by traffic.”
Fact: Pollution may come from natural, industrial, and domestic sources, often in combination.
Managing your condition during high air pollution
For people with aspergillosis, asthma, bronchiectasis or other lung conditions, air pollution can trigger symptoms even when there is no infection. Having a simple plan can help you feel more in control.
Continue your regular medication
- Take your prescribed medications as usual, including inhalers or antifungal treatments
- Do not stop or reduce medication without medical advice
Have your reliever medication available
- Carry your reliever inhaler (if prescribed) when leaving the house
- Make sure it is within easy reach, not packed away
- Check that it is in date and not empty
Plan ahead before going outdoors
- Check the AQI before leaving home
- Avoid going out during peak pollution times if possible
- Consider shorter trips or lower-exertion activities
Adjust activity levels
- Reduce strenuous activity when AQI is high
- Walk more slowly and allow extra time
- Take breaks if you feel breathless
Know your early warning signs
Be aware of symptoms that may indicate your lungs are being affected:
- Increased breathlessness
- More coughing or wheezing
- Chest tightness
- Unusual fatigue
Have a simple action plan
- Know what you usually do if symptoms worsen
- Follow any personalised plan provided by your clinical team
- Seek advice if symptoms are different from your usual pattern
Practical tip: On high pollution days, think ahead before leaving home—take medication with you, plan shorter trips, and allow extra time so you do not have to rush.
When to seek medical help
Seek medical advice promptly if you notice:
- Worsening breathlessness
- New or worsening wheeze
- Chest tightness that is not settling
- A major increase in cough
- Coughing blood (haemoptysis)
- Symptoms that are more severe than your usual pattern
If you have a severe flare, marked breathing difficulty, or significant haemoptysis, seek urgent medical help.
Final takeaway
Outdoor air pollution is an important and often under-recognised trigger for people with lung disease. For patients with aspergillosis and related lung conditions, it can worsen symptoms even when there is no new infection.
The most helpful practical points are:
- Use AQI rather than appearance alone
- Remember that pollution may be visible or invisible
- Stay indoors when AQI is high
- Use air filtration where possible
- Keep an eye on changing symptoms and seek help if needed
References
- World Health Organization. WHO Global Air Quality Guidelines. 2021.
- UK Department for Environment, Food & Rural Affairs (DEFRA). UK-AIR: Air Information Resource.
- IQAir AirVisual air quality app.
- European Respiratory Society statements and guidance on air pollution and respiratory health.
- British Thoracic Society resources on respiratory health and environmental exposure.
Author: Prepared for aspergillosis.org
Review note: This article is intended for general education and should not replace advice from your own clinical team.
Voriconazole interactions: what patients need to know
Key points
- Voriconazole interacts with many medicines.
- It affects several liver enzyme pathways, including CYP3A4, CYP2C19, and CYP2C9.
- Its behaviour can vary more from one person to another than some other azoles.
- Some medicines can make voriconazole stronger, while others can make it less effective.
- Visual side effects and sensitivity to sunlight are well recognised with voriconazole.
What is voriconazole?
Voriconazole is an azole antifungal often used in serious fungal infections, including aspergillosis. It can be very effective, but it also has a relatively complex interaction profile.
Why voriconazole interacts with so many medicines
Voriconazole affects several liver enzyme systems, including CYP3A4, CYP2C19, and CYP2C9. It can increase the levels of some medicines, while some other medicines can lower voriconazole levels and reduce its effectiveness.
Because voriconazole metabolism varies between patients, the same combination can affect people differently.
The interaction groups most likely to matter
Steroids
Voriconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.
Medicines that reduce voriconazole levels
Some medicines, including certain anti-seizure medicines and rifampicin-type antibiotics, can reduce voriconazole levels so much that the antifungal may not work properly.
Blood thinners
Some blood thinners may become stronger when taken with voriconazole, increasing bleeding risk.
Heart rhythm medicines
Voriconazole can contribute to QT prolongation, so combinations with other medicines that affect heart rhythm may be particularly important.
Statins
Some statins can become stronger when taken with voriconazole, increasing the risk of muscle side effects.
Immunosuppressants
Medicines such as tacrolimus and ciclosporin can rise significantly with voriconazole and often require specialist monitoring and dose adjustment.
Sedatives and some mental health medicines
Some sedatives and psychiatric medicines can become stronger when combined with voriconazole, increasing the risk of drowsiness, confusion, or other side effects.
Voriconazole-specific issues patients should know
Visual changes
Temporary visual disturbances are well recognised with voriconazole. Patients may notice blurred vision, brighter vision, or changes in colour perception.
Photosensitivity
Voriconazole can increase sensitivity to sunlight. Patients should use sensible sun protection and report new skin changes, especially during long-term treatment.
Variable drug levels
Voriconazole levels can vary between patients, which is one reason some teams use therapeutic drug monitoring in selected situations.
What patients should do in practice
- Tell your clinical team and pharmacist that you are taking voriconazole.
- Check before starting new medicines, including over-the-counter or herbal products.
- Report visual changes, significant sensitivity to sunlight, or a change in symptoms after a medicine change.
- Do not change treatment without advice.
When to seek medical advice
Seek medical advice urgently for severe bleeding, fainting, severe palpitations, marked confusion, or rapid worsening after a medicine change.
Important
This page is educational and does not list every interaction. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.
References
Itraconazole interactions: what patients need to know
Key points
- Itraconazole can interact with many other medicines.
- It usually does this by affecting liver enzymes, especially CYP3A4.
- Some combinations need careful monitoring, while others are best avoided.
- Capsules and liquid formulations are not handled by the body in exactly the same way.
- This page highlights the interactions most likely to matter to people with aspergillosis.
What is itraconazole?
Itraconazole is an azole antifungal used in aspergillosis and other fungal infections. It has a relatively high interaction burden, so medicine checks are especially important before starting it and whenever another medicine is added, stopped, or changed.
Why itraconazole interacts with so many medicines
Itraconazole can increase the levels of some other medicines by affecting liver enzymes, especially CYP3A4. This means that some medicines may become stronger than intended, which can increase the risk of side effects or toxicity.
The interaction groups most likely to matter
Steroids and inhalers
This is one of the most important groups for many aspergillosis patients, especially those with asthma or allergic bronchopulmonary aspergillosis. Itraconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.
Possible symptoms to report: unusual weight gain, easy bruising, increased facial rounding, mood changes, worsening blood sugar control, weakness, or marked fatigue.
Statins
Some statins can become much stronger when taken with itraconazole. This can increase the risk of muscle toxicity.
Possible symptoms to report: new muscle pain, muscle weakness, or dark urine.
Blood thinners
Itraconazole can increase the effect of some blood thinners, which may raise bleeding risk.
Possible symptoms to report: unusual bruising, bleeding that is hard to stop, black stools, vomiting blood, or coughing up much more blood than usual.
Heart and rhythm medicines
Some combinations can increase the risk of serious heart rhythm problems. Itraconazole is also used cautiously in people with a history of ventricular dysfunction or heart failure unless the infection is serious.
Possible symptoms to report: fainting, palpitations, marked dizziness, increasing ankle swelling, or worsening breathlessness.
Sleeping tablets, sedatives, and some mental health medicines
Some sedatives and psychotropic medicines can become stronger when combined with itraconazole, increasing the risk of drowsiness, confusion, falls, or breathing problems.
Immunosuppressants
Medicines such as tacrolimus and ciclosporin can rise significantly when taken with itraconazole and usually need specialist monitoring.
Medicines that can make itraconazole less effective
Some medicines lower itraconazole levels, which means the antifungal may not work as well. This can happen with some anti-seizure medicines, rifampicin-type antibiotics, and some antiviral medicines.
Acid-reducing medicines and itraconazole capsules
Reduced stomach acid can lower the absorption of itraconazole capsules. This means reflux medicines, antacids, and some acid-suppressing treatments can affect how well the capsules work. The liquid formulation behaves differently and should not be treated as interchangeable with capsules.
What patients should do in practice
- Keep a current medicines list and bring it to appointments.
- Tell clinicians and pharmacists if you are taking itraconazole.
- Ask specifically about inhalers, steroid tablets, statins, blood thinners, and reflux treatment.
- Do not change doses or stop medicines without advice.
- If your itraconazole formulation changes, ask whether it should be taken with food or on an empty stomach.
When to seek medical advice
Seek urgent medical advice for severe bleeding, black stools, vomiting blood, severe muscle pain, fainting, marked palpitations, or rapidly worsening breathlessness.
Important
This page is not a full interaction database. For a complete medicine-by-medicine check, use the BNF interaction checker or speak to a pharmacist or clinician.










